TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02870049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inreach strategy
Description: Inreach strategy: In clinic education and delivery of fecal immunochemical test (FIT) kit

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outreach strategy
Description: Outreach strategy: Mailed fecal immunochemical test (FIT) kit and telephone reminders

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Both Inreach and Outreach strategies
Description: Both Inreach and Outreach strategies: Both In clinic education and delivery of fecal immunochemical test (FIT) kit and Mailed fecal immunochemical test (FIT) kit and telephone reminders

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care: FIT kit delivery as part of usual care
Study: NCT02327052

Intervention type: OTHER
Intervention: No intervention was performed.
Description: No intervention was performed.
Study: NCT04277520

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root canal therapy
Description: Different types of instrumentation motions during root canal therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root canal therapy
Description: Different types of instrumentation motions during root canal therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root canal therapy
Description: Different types of instrumentation motions during root canal therapy
Study: NCT03640598

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ilioinguinal/iliohypogastric nerve blocks
Description: The patient will receive ultrasound-guided Ilioinguinal/iliohypogastric nerve blocks with0.5 ml/kg 0.125 mg/kg bupivacaine + fentanyl 2ug/ml injectate

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Erector spinae nerve block
Description: The patient will receive ultrasound-guided erector spinae nerve block 0.5 ml/kg 0.125 bupivacaine + fentanyl 2ug/ml injectate.
Study: NCT01504165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide 2000mg
Description: A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide 2000mg
Description: A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide 2000mg
Description: A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide 1000mg
Description: A single dose of cilengitide 1000mg (125mL) will be administered as 1-hour i.v. infusion on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide > 1000mg and up to 2000mg
Description: A single dose of cilengitide \> 1000mg and up to 2000mg will be administered as 1-hour i.v. infusion on Day 1 if applicable, based on Safety Monitoring Committee decision
Study: NCT00817882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: individually targeted vocational rehabilitation
Description: individually targeted vocational rehabilitation over 4 month period, maximum of 10 sessions, in addition to routine back pain rehabilitation.~Maximum of 25 participants with low back pain

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine back pain rehabilitation
Description: routine back pain rehabilitation Maximum of 25 patients with low back pain
Study: NCT01427465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Prevention Program Using Positive Image
Description: Consult

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Prevention Program Using Positive Image
Description: Control - Standard of Care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Prevention Program Using Positive Image
Description: Newsletter

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Prevention Program Using Positive Image
Description: Parent Letter
Study: NCT03341975

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SexHealth
Description: To enhance and test our ED SexHealth intervention that provides risk reduction counseling and point-of-care services as well as connections to sustainable, non-episodic sources of care.
Study: NCT01382797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 37
Description: Capsules for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules for oral administration
Study: NCT04514120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AJESS scoring process
Description: We will collecto endoscopic pictures from stable and non stable participants. Pictures will be taken for each sinus, olfactory cleft, and middle meatus in private clinical exam rooms. For each anatomic site \[left middle meatus (LMM), left ethmoid sinus (LES), left frontal sinus (LFS), left maxillary sinus (LMS), left olfactory cleft (LOC), left sphenoid sinus (LSS), right middle meatus (RMM), right ethmoid sinus (RES), right frontal sinus (RFS), right maxillary sinus (RMS), right olfactory cleft (ROC), right sphenoid sinus (RSS)\], numerical scores describe edema or polyposis while alphabetical scores, in lower case or upper case corresponding to severity, describe CRS features: crusting, synechiae, purulence, mucus, recirculation, and ostial narrowness.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AJESS scoring process
Description: We will collecto endoscopic pictures from stable and non stable participants. Pictures will be taken for each sinus, olfactory cleft, and middle meatus in private clinical exam rooms. For each anatomic site \[left middle meatus (LMM), left ethmoid sinus (LES), left frontal sinus (LFS), left maxillary sinus (LMS), left olfactory cleft (LOC), left sphenoid sinus (LSS), right middle meatus (RMM), right ethmoid sinus (RES), right frontal sinus (RFS), right maxillary sinus (RMS), right olfactory cleft (ROC), right sphenoid sinus (RSS)\], numerical scores describe edema or polyposis while alphabetical scores, in lower case or upper case corresponding to severity, describe CRS features: crusting, synechiae, purulence, mucus, recirculation, and ostial narrowness.
Study: NCT03069352

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cytarabine
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Subcutaneous injection
Study: NCT02127671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IDEAL intervention

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Study: NCT00801645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise groups engage in aerobic exercise training three 60-minute sessions per week for 12 weeks, in addition of school physical education. Training sessions consist of 30 minutes of aerobic exercise (walking, running, games, swimming), followed by strength training and stretching.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise groups engage in aerobic exercise training three 60-minute sessions per week for 12 weeks, in addition of school physical education. Training sessions consist of 30 minutes of aerobic exercise (walking, running, games, swimming), followed by strength training and stretching.
Study: NCT04213105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1206
Description: subcutaneous injection of 60 mg (1ml) only once,on the first day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolia®
Description: subcutaneous injection of 60 mg (1ml)only once,on the first day
Study: NCT02821923

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: E967-Xylitol
Description: 24g xylitol/d

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: E968-Erythritol
Description: 36g erythritol/d
Study: NCT02663453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: multicomponent lipid emulsion
Description: Lipids were first administered at a dose of 1gm/kg/day within 24 hours after birth for both groups; lipid dosage was increased by an increment of 0.5 gm/kg/day until the maximal dose of 3.5 gm/kg/day was reached.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pure soybean oil lipid emulsion
Description: Lipids were first administered at a dose of 1gm/kg/day within 24 hours after birth for both groups; lipid dosage was increased by an increment of 0.5 gm/kg/day until the maximal dose of 3.5 gm/kg/day was reached.
Study: NCT00995475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone propionate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00336219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: Symptom Assessment after treatment with Pantoprozole 40 mg
Study: NCT03502291

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Study one: LAIV + Inoculation
Description: Pneumococci bacteria nasal inoculation following vaccination with LAIV and intramuscular placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Study one: Placebo + Inoculation
Description: Pneumococci bacteria nasal inoculation following vaccination QIV with nasal placebo spray

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Study two: Inoculation + LAIV
Description: Pneumococci bacteria nasal inoculation prior to vaccination with LAIV and intramuscular placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Study two: Inoculation + placebo
Description: Pneumococci bacteria nasal inoculation prior to vaccination QIV with nasal placebo
Study: NCT02800070

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lentivirus Alpha-gal A transduced stem cells
Study: NCT01390766

Intervention type: DRUG
Intervention: Azathioprine
Study: NCT04053647

Intervention type: OTHER
Intervention: Non-interventional study
Description: Non-interventional study

Intervention type: OTHER
Intervention: Non-interventional study
Description: Non-interventional study
Study: NCT02088970

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crosslinking
Description: The procedure of the cross linking is standard:combined riboflavin(Ricrolin®)-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 or 5.4 joule/cm2 for a 30-minute exposure irradiation of the cornea.~Patients are checked every days during the hospitalisation and one week, one month and 3 months after the hospitalisation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antibiotic treatment
Description: If not the contact lens wearer -\> Cocci Gram positive cocci~* Vancomycin + Fortum~If contact lens wearer -\> Gram negative bacillus~* Fortum + Amiklin~If corticosteroids, immunosuppression, latent evolution -\> Fungus.~= Fortum + vancomycin + Fungizone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antibiotic treatment
Description: If not the contact lens wearer -\> Cocci Gram positive cocci~* Vancomycin + Fortum~If contact lens wearer -\> Gram negative bacillus~* Fortum + Amiklin~If corticosteroids, immunosuppression, latent evolution -\> Fungus.~= Fortum + vancomycin + Fungizone
Study: NCT05597475

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: GLP-1R PET
Description: Beta cell function (tests) and measure for beta cell mass (PET)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: GLP-1R PET
Description: Beta cell function (tests) and measure for beta cell mass (PET)
Study: NCT03203057

Intervention type: OTHER
Intervention: coronary occlusion
Description: percutaneous coronary intervention

Intervention type: OTHER
Intervention: coronary occlusion
Description: percutaneous coronary intervention

Intervention type: OTHER
Intervention: coronary occlusion
Description: percutaneous coronary intervention
Study: NCT02524821

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelesis100
Description: 3 capsules each containing 0.75 mg

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gelesis100
Description: 3 capsules each containing 0.75 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 1 tablet of 850 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 1 tablet of 850 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 1 tablet of 850 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 1 tablet of 850 mg
Study: NCT04699019

Intervention type: OTHER
Intervention: Four speeds
Description: Four speeds ranging from a set walking speed up to 9 mph

Intervention type: OTHER
Intervention: Foot Strike Pattern
Description: Foot strike sequences (rearfoot strike, midfoot strike, forefoot strike)
Study: NCT03417908

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PNF
Description: The contract-relax method of proprioceptive neuromuscular facilitation (PNF) technique will be used for stretching of ESC, ECM and external intercostals muscles. The contraction of agonist muscles against the resistance imposed by the physiotherapist (isometric contraction) will be maintained for 6 seconds. After that, the patient is oriented to relax the muscles for 6 seconds without losing range of motion, and then the muscle will be lengthened. This procedure is repeated until the maximum amplitude of motion of the neck and upper limb is reached. The stretching will be performed on the right and left sides of the body.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PNF
Description: The contract-relax method of proprioceptive neuromuscular facilitation (PNF) technique will be used for stretching of ESC, ECM and external intercostals muscles. The contraction of agonist muscles against the resistance imposed by the physiotherapist (isometric contraction) will be maintained for 6 seconds. After that, the patient is oriented to relax the muscles for 6 seconds without losing range of motion, and then the muscle will be lengthened. This procedure is repeated until the maximum amplitude of motion of the neck and upper limb is reached. The stretching will be performed on the right and left sides of the body.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Isotonic concentric contraction of the biceps (two sets of five push-ups elbow in both arms) with the individual sitting in a chair with back support.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Isotonic concentric contraction of the biceps (two sets of five push-ups elbow in both arms) with the individual sitting in a chair with back support.
Study: NCT01991990

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single i.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: Single 8 mg/kg i.v. infusion
Study: NCT01967355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lipid apheresis
Study: NCT02348892

Intervention type: OTHER
Intervention: Coordinator
Description: Patients in complex situation taken care by coordinator

Intervention type: OTHER
Intervention: Classic plan
Description: Patients in complex situation taken care by classic plan
Study: NCT00888550

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post-Op Splinting
Description: Splint will applied post-operatively and will remain on for two weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No Splinting
Description: Patient will be discharged post-operatively without a splint on their lower leg.
Study: NCT00942175

Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel
Description: Clopidogrel 75 mg, tablets, orally, once daily days 1-9.

Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel and Lansoprazole
Description: Clopidogrel 75 mg, tablets, orally, once daily and Lansoprazole 30 mg, capsules, orally, once daily days 1-9.

Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel and Dexlansoprazole
Description: Clopidogrel 75 mg, tablets, orally, once daily and Dexlansoprazole 60 mg, capsules, orally, once daily days 1-9.

Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel and Omeprazole
Description: Clopidogrel 75 mg, tablets, orally, once daily and Omeprazole 80 mg, capsules, orally, once daily days 1-9.

Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel and Esomeprazole
Description: Clopidogrel 75 mg, tablets, orally, once daily and Esomeprazole 40 mg, capsules, orally, once daily days 1-9.
Study: NCT03581266

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rye/Wheat
Description: Mechanistic study of glucose kinetics after ingestion two kinds of bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rye/Wheat
Description: Mechanistic study of glucose kinetics after ingestion two kinds of bread
Study: NCT01066585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin Cream
Description: Up to 4 ounces of topical 0.5% Ivermectin Cream applied to the hair and scalp on day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle control
Description: Up to 4 ounces of vehicle control applied to the hair and scalp on day 1
Study: NCT02305095

Intervention type: DRUG
Intervention: FDC I/H
Description: All subjects in both groups will be initiated on drug, FDC I/H with dose titrated up to target doses based on clinical guidelines

Intervention type: DRUG
Intervention: FDC I/H
Description: All subjects in both groups will be initiated on drug, FDC I/H with dose titrated up to target doses based on clinical guidelines
Study: NCT01833611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: entecavir 0.5mg qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo qd
Study: NCT04489745

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Study: NCT01891500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Description: Drug is initiated at 20ppm. Patients randomized to receive iNO at OI 10-15.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitrogen Gas
Description: Placebo gas (bioinert), Patients randomized to bioinert inhaled gas at OI 10-15.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crossover iNO
Description: Patients who deteriorate (OI \>20 on two consecutive blood gases) will be unblinded. If they are receiving placebo gas, they will be started on iNO and make up the crossover cohort.
Study: NCT03521375

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Surgery
Description: Conventional open surgery is undertaken through a single incision +/- rib resection and with rib spreading. The operation is performed under direct vision with isolation of the hilar structures (vein, artery and bronchus) which are dissected, ligated and divided in sequence and the lobe of lung resected. The procedures may be undertaken using ligatures, over sewing or with staplers. Lymph node management is undertaken in accordance with the International Association of the Study of Lung Cancer (IASLC) recommendations where a minimal of 6 nodes / stations are removed, of which 3 are from the mediastinum that includes the subcarinal station. The thoracotomy is closed in layers starting from pericostal sutures over the ribs, muscle, fat and skin layers.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video Assisted Thoracoscopic Surgery (VATS)
Description: VATS lobectomy is undertaken through one to four keyhole incisions without rib spreading. The use of 'rib spreading' is prohibited as this is the key intra-operative manoeuvre which disrupts tissues and causes pain (and is used in open surgery). The procedure is performed with videoscopic visualisation without direct vision. The hilar structures are dissected, stapled and divided. Endoscopic ligation of pulmonary arterial branches may be performed. The fissure is completed and the lobe of lung resected. Lymph node management is the same as described for open surgery. The incisions are closed in layers and may involve muscle, fat and skin layers. This definition of VATS lobectomy is a modification of CALGB 39802.
Study: NCT03821025

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary stent
Description: Palliation of malignant biliary obstruction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary stent
Description: Palliation of malignant biliary obstruction
Study: NCT03104894

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meibomian Glands Massage
Description: Meibomian gland expression

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Meibomian Glands Massage
Description: Touching the eyelids gently

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Meibomian Massage device
Description: Meibomian glands expression with applicator
Study: NCT04126083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine Oral Tablet
Description: lofexidine 0.54 mg 4 times daily
Study: NCT02873936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: csDMARDs
Description: csDMARDs may include one or two of the following: methotrexate (MTX), hydroxychloroquine or chloroquine, sulfasalazine, and/or leflunomide (combination of leflunomide and MTX is not allowed)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: csDMARDs
Description: csDMARDs may include one or two of the following: methotrexate (MTX), hydroxychloroquine or chloroquine, sulfasalazine, and/or leflunomide (combination of leflunomide and MTX is not allowed)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: csDMARDs
Description: csDMARDs may include one or two of the following: methotrexate (MTX), hydroxychloroquine or chloroquine, sulfasalazine, and/or leflunomide (combination of leflunomide and MTX is not allowed)